NWBO - Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated ...
Model output · Signal date 2026-10-14
Northwest Biotherapeutics Inc (NWBO) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
Rating · 90D
Total
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Middle 30%
of 4009 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$277M
small-cap · #60 of 60 peers
Summary
Northwest Biotherapeutics Inc (NWBO) stock forecast summary
On Oct. 14, 2026, NWBO is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Northwest Biotherapeutics Inc is a small-cap company with a market capitalization of $277M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Current Ratio of 0.04x is the lowest of the 50 peers that report one.
A per-ticker accuracy statistic for NWBO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NWBO included.
Follow NWBO freePrice
NWBO price chart and AI forecast
Cross-section · 2026-10-14
How NWBO ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Northwest Biotherapeutics Inc (NWBO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | NWBO | Rank |
|---|---|---|
| Market Cap | $277M | 60/60 |
| EPS | $-0.02 | – |
Profitability & Margins
| Metric | NWBO | Rank |
|---|---|---|
| Operating Margin | -3033.7% | 31/33 |
| EBT Margin | -3033.7% | 38/40 |
Financial Health
| Metric | NWBO | Rank |
|---|---|---|
| Current Ratio | 0.04x | 50/50 |
| Interest Coverage | -10.4x | 24/36 |
| Working Capital | -$71M | 48/50 |
Cash Flow
| Metric | NWBO | Rank |
|---|---|---|
| Operating Cash Flow | -$53M | 30/49 |
Income Statement
| Metric | NWBO | Rank |
|---|---|---|
| Operating Income | -$51M | 22/41 |
| R&D Expense | $25M | 47/48 |
Dividend & Shareholder Information
| Metric | NWBO | Rank |
|---|---|---|
| Shares Outstanding | 1706M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3M | 3.4% of assets |
| Cash & Short-term Investments | $590K | 0.8% of assets |
| Total Liabilities | $111M | 145.8% of assets |
| Short-term Debt | $41M | 53.8% of assets |
Quarterly Financial Reports
NWBO quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Northwest Biotherapeutics Inc (NWBO) industry peers
Companies classified under the same SEC industry code as Northwest Biotherapeutics Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NWBO Northwest Biotherapeutics Inc | ▶ | $277M |
| LLY Eli Lilly & Co | ▶ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.83B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▼ | $178.73B |
| PFE Pfizer Inc | ▶ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▶ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▶ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▼ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▲ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.79B |
| ABVX Abivax S.A. | ▼ | $6.77B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▲ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where NWBO sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Northwest Biotherapeutics Inc (NWBO) stock news
Northwest Biotherapeutics, Advent Bioservices And The UK National Health Service Blood And Transplant Announce Collaboration To Support DCVax®-L Production
The collaboration between NHSBT and Northwest Biotherapeutics brings together this clinical and operational expertise with the work of NWBio and Advent Bioservices in developing DCVax®-L in the UK.
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
BETHESDA, Md., April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid ...
FAQ
Northwest Biotherapeutics Inc (NWBO) stock forecast FAQ
What is the Northwest Biotherapeutics Inc (NWBO) stock forecast?
On Oct. 14, 2026, NWBO is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Northwest Biotherapeutics Inc stock predictions?
A per-ticker accuracy statistic for NWBO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Northwest Biotherapeutics Inc forecasts updated?
Northwest Biotherapeutics Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Northwest Biotherapeutics Inc's industry peers?
60 issuers in our coverage, NWBO included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.